nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—TEK—epilepsy syndrome	0.132	0.336	CbGaD
Regorafenib—RET—epilepsy syndrome	0.122	0.312	CbGaD
Regorafenib—KDR—epilepsy syndrome	0.0643	0.164	CbGaD
Regorafenib—ABCG2—epilepsy syndrome	0.0336	0.0856	CbGaD
Regorafenib—CYP2C19—epilepsy syndrome	0.0264	0.0673	CbGaD
Regorafenib—UGT1A9—Propofol—epilepsy syndrome	0.0202	0.0575	CbGbCtD
Regorafenib—UGT1A1—Propofol—epilepsy syndrome	0.0165	0.047	CbGbCtD
Regorafenib—UGT1A9—Valproic Acid—epilepsy syndrome	0.0144	0.0411	CbGbCtD
Regorafenib—ABCB1—epilepsy syndrome	0.014	0.0356	CbGaD
Regorafenib—CYP2B6—Fosphenytoin—epilepsy syndrome	0.0106	0.0303	CbGbCtD
Regorafenib—CYP2B6—Clobazam—epilepsy syndrome	0.00922	0.0262	CbGbCtD
Regorafenib—CYP2C8—Trimethadione—epilepsy syndrome	0.00857	0.0244	CbGbCtD
Regorafenib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00806	0.0229	CbGbCtD
Regorafenib—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.00773	0.022	CbGbCtD
Regorafenib—CYP2B6—Carbamazepine—epilepsy syndrome	0.00764	0.0217	CbGbCtD
Regorafenib—CYP2C19—Felbamate—epilepsy syndrome	0.00719	0.0205	CbGbCtD
Regorafenib—CYP2C19—Trimethadione—epilepsy syndrome	0.00719	0.0205	CbGbCtD
Regorafenib—CYP2B6—Primidone—epilepsy syndrome	0.00713	0.0203	CbGbCtD
Regorafenib—CYP2B6—Phenytoin—epilepsy syndrome	0.00685	0.0195	CbGbCtD
Regorafenib—ABCB1—Levetiracetam—epilepsy syndrome	0.00682	0.0194	CbGbCtD
Regorafenib—CYP2C19—Fosphenytoin—epilepsy syndrome	0.00676	0.0192	CbGbCtD
Regorafenib—CYP2B6—Propofol—epilepsy syndrome	0.00639	0.0182	CbGbCtD
Regorafenib—CYP2B6—Phenobarbital—epilepsy syndrome	0.00611	0.0174	CbGbCtD
Regorafenib—CYP2B6—Midazolam—epilepsy syndrome	0.00602	0.0171	CbGbCtD
Regorafenib—CYP2C9—Trimethadione—epilepsy syndrome	0.00598	0.017	CbGbCtD
Regorafenib—CYP2C19—Clobazam—epilepsy syndrome	0.00586	0.0167	CbGbCtD
Regorafenib—CYP2B6—Diazepam—epilepsy syndrome	0.00579	0.0165	CbGbCtD
Regorafenib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00579	0.0165	CbGbCtD
Regorafenib—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00562	0.016	CbGbCtD
Regorafenib—CYP2C8—Primidone—epilepsy syndrome	0.0054	0.0154	CbGbCtD
Regorafenib—CYP2C8—Phenytoin—epilepsy syndrome	0.00519	0.0148	CbGbCtD
Regorafenib—CYP2C19—Carbamazepine—epilepsy syndrome	0.00485	0.0138	CbGbCtD
Regorafenib—CYP2C8—Propofol—epilepsy syndrome	0.00484	0.0138	CbGbCtD
Regorafenib—ABCB1—Clobazam—epilepsy syndrome	0.00473	0.0135	CbGbCtD
Regorafenib—CYP2C8—Phenobarbital—epilepsy syndrome	0.00463	0.0132	CbGbCtD
Regorafenib—CYP2B6—Valproic Acid—epilepsy syndrome	0.00456	0.013	CbGbCtD
Regorafenib—ABCB1—Lamotrigine—epilepsy syndrome	0.00455	0.013	CbGbCtD
Regorafenib—CYP2C19—Primidone—epilepsy syndrome	0.00453	0.0129	CbGbCtD
Regorafenib—CYP2C8—Diazepam—epilepsy syndrome	0.00439	0.0125	CbGbCtD
Regorafenib—CYP2C19—Phenytoin—epilepsy syndrome	0.00435	0.0124	CbGbCtD
Regorafenib—CYP2C19—Propofol—epilepsy syndrome	0.00406	0.0116	CbGbCtD
Regorafenib—CYP2C9—Carbamazepine—epilepsy syndrome	0.00404	0.0115	CbGbCtD
Regorafenib—ABCB1—Carbamazepine—epilepsy syndrome	0.00392	0.0111	CbGbCtD
Regorafenib—CYP2C19—Phenobarbital—epilepsy syndrome	0.00388	0.011	CbGbCtD
Regorafenib—CYP2C9—Primidone—epilepsy syndrome	0.00377	0.0107	CbGbCtD
Regorafenib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00374	0.0106	CbGbCtD
Regorafenib—CYP2C19—Diazepam—epilepsy syndrome	0.00368	0.0105	CbGbCtD
Regorafenib—CYP2C9—Phenytoin—epilepsy syndrome	0.00362	0.0103	CbGbCtD
Regorafenib—CYP2C19—Zonisamide—epilepsy syndrome	0.00359	0.0102	CbGbCtD
Regorafenib—ABCB1—Phenytoin—epilepsy syndrome	0.00351	0.01	CbGbCtD
Regorafenib—CYP3A4—Felbamate—epilepsy syndrome	0.00347	0.00989	CbGbCtD
Regorafenib—CYP3A4—Trimethadione—epilepsy syndrome	0.00347	0.00989	CbGbCtD
Regorafenib—CYP2C8—Valproic Acid—epilepsy syndrome	0.00346	0.00984	CbGbCtD
Regorafenib—CYP2C9—Propofol—epilepsy syndrome	0.00338	0.00961	CbGbCtD
Regorafenib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00327	0.0093	CbGbCtD
Regorafenib—CYP2C9—Phenobarbital—epilepsy syndrome	0.00323	0.00918	CbGbCtD
Regorafenib—ABCB1—Phenobarbital—epilepsy syndrome	0.00313	0.00891	CbGbCtD
Regorafenib—ABCB1—Midazolam—epilepsy syndrome	0.00309	0.00879	CbGbCtD
Regorafenib—CYP2C9—Diazepam—epilepsy syndrome	0.00306	0.00871	CbGbCtD
Regorafenib—ABCB1—Diazepam—epilepsy syndrome	0.00297	0.00845	CbGbCtD
Regorafenib—CYP3A4—Clonazepam—epilepsy syndrome	0.00295	0.00841	CbGbCtD
Regorafenib—CYP2C19—Valproic Acid—epilepsy syndrome	0.0029	0.00825	CbGbCtD
Regorafenib—CYP3A4—Clobazam—epilepsy syndrome	0.00283	0.00806	CbGbCtD
Regorafenib—CYP2C19—Topiramate—epilepsy syndrome	0.00262	0.00745	CbGbCtD
Regorafenib—CYP2C9—Valproic Acid—epilepsy syndrome	0.00241	0.00686	CbGbCtD
Regorafenib—CYP3A4—Rufinamide—epilepsy syndrome	0.00241	0.00685	CbGbCtD
Regorafenib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00235	0.00668	CbGbCtD
Regorafenib—CYP3A4—Primidone—epilepsy syndrome	0.00219	0.00624	CbGbCtD
Regorafenib—CYP3A4—Phenytoin—epilepsy syndrome	0.00211	0.00599	CbGbCtD
Regorafenib—FGFR2—skull—epilepsy syndrome	0.00207	0.0488	CbGeAlD
Regorafenib—RET—autonomic nervous system—epilepsy syndrome	0.00204	0.0481	CbGeAlD
Regorafenib—CYP3A4—Propofol—epilepsy syndrome	0.00196	0.00559	CbGbCtD
Regorafenib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00188	0.00534	CbGbCtD
Regorafenib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00188	0.00534	CbGbCtD
Regorafenib—CYP3A4—Midazolam—epilepsy syndrome	0.00185	0.00527	CbGbCtD
Regorafenib—CYP3A4—Diazepam—epilepsy syndrome	0.00178	0.00506	CbGbCtD
Regorafenib—CYP3A4—Zonisamide—epilepsy syndrome	0.00174	0.00494	CbGbCtD
Regorafenib—CYP3A4—Valproic Acid—epilepsy syndrome	0.0014	0.00399	CbGbCtD
Regorafenib—CYP3A4—Topiramate—epilepsy syndrome	0.00127	0.0036	CbGbCtD
Regorafenib—Sorafenib—RET—epilepsy syndrome	0.00105	0.385	CrCbGaD
Regorafenib—FGFR2—hindbrain—epilepsy syndrome	0.000817	0.0193	CbGeAlD
Regorafenib—NTRK1—midbrain—epilepsy syndrome	0.000786	0.0185	CbGeAlD
Regorafenib—MAPK11—telencephalon—epilepsy syndrome	0.000771	0.0182	CbGeAlD
Regorafenib—RAF1—hindbrain—epilepsy syndrome	0.000753	0.0178	CbGeAlD
Regorafenib—DDR2—spinal cord—epilepsy syndrome	0.00057	0.0134	CbGeAlD
Regorafenib—KIT—hindbrain—epilepsy syndrome	0.000568	0.0134	CbGeAlD
Regorafenib—Sorafenib—KDR—epilepsy syndrome	0.00055	0.202	CrCbGaD
Regorafenib—DDR2—head—epilepsy syndrome	0.000507	0.0119	CbGeAlD
Regorafenib—ABL1—hindbrain—epilepsy syndrome	0.000494	0.0116	CbGeAlD
Regorafenib—FGFR1—telencephalon—epilepsy syndrome	0.000489	0.0115	CbGeAlD
Regorafenib—DDR2—nervous system—epilepsy syndrome	0.00048	0.0113	CbGeAlD
Regorafenib—MAPK11—head—epilepsy syndrome	0.00048	0.0113	CbGeAlD
Regorafenib—FGFR2—brainstem—epilepsy syndrome	0.000469	0.011	CbGeAlD
Regorafenib—DDR2—central nervous system—epilepsy syndrome	0.000463	0.0109	CbGeAlD
Regorafenib—MAPK11—nervous system—epilepsy syndrome	0.000455	0.0107	CbGeAlD
Regorafenib—FGFR2—forebrain—epilepsy syndrome	0.000452	0.0107	CbGeAlD
Regorafenib—DDR2—cerebellum—epilepsy syndrome	0.000452	0.0107	CbGeAlD
Regorafenib—MAPK11—central nervous system—epilepsy syndrome	0.000438	0.0103	CbGeAlD
Regorafenib—RAF1—brainstem—epilepsy syndrome	0.000432	0.0102	CbGeAlD
Regorafenib—MAPK11—cerebellum—epilepsy syndrome	0.000429	0.0101	CbGeAlD
Regorafenib—RAF1—forebrain—epilepsy syndrome	0.000417	0.00982	CbGeAlD
Regorafenib—FGFR2—telencephalon—epilepsy syndrome	0.000416	0.0098	CbGeAlD
Regorafenib—BRAF—midbrain—epilepsy syndrome	0.000413	0.00973	CbGeAlD
Regorafenib—TEK—telencephalon—epilepsy syndrome	0.000399	0.00939	CbGeAlD
Regorafenib—PDGFRA—forebrain—epilepsy syndrome	0.000393	0.00926	CbGeAlD
Regorafenib—FLT1—telencephalon—epilepsy syndrome	0.000385	0.00908	CbGeAlD
Regorafenib—FGFR1—medulla oblongata—epilepsy syndrome	0.000384	0.00905	CbGeAlD
Regorafenib—RAF1—telencephalon—epilepsy syndrome	0.000383	0.00903	CbGeAlD
Regorafenib—DDR2—brain—epilepsy syndrome	0.000367	0.00865	CbGeAlD
Regorafenib—PDGFRA—telencephalon—epilepsy syndrome	0.000361	0.00851	CbGeAlD
Regorafenib—KDR—forebrain—epilepsy syndrome	0.000354	0.00835	CbGeAlD
Regorafenib—FGFR1—midbrain—epilepsy syndrome	0.000351	0.00828	CbGeAlD
Regorafenib—MAPK11—brain—epilepsy syndrome	0.000348	0.0082	CbGeAlD
Regorafenib—RET—medulla oblongata—epilepsy syndrome	0.000344	0.0081	CbGeAlD
Regorafenib—FGFR1—spinal cord—epilepsy syndrome	0.000343	0.00807	CbGeAlD
Regorafenib—KIT—brainstem—epilepsy syndrome	0.000325	0.00767	CbGeAlD
Regorafenib—Sorafenib—ABCC2—epilepsy syndrome	0.000325	0.119	CrCbGaD
Regorafenib—BRAF—cerebellum—epilepsy syndrome	0.00032	0.00753	CbGeAlD
Regorafenib—RET—midbrain—epilepsy syndrome	0.000314	0.00741	CbGeAlD
Regorafenib—TEK—medulla oblongata—epilepsy syndrome	0.000313	0.00738	CbGeAlD
Regorafenib—FLT4—head—epilepsy syndrome	0.000309	0.00727	CbGeAlD
Regorafenib—RET—spinal cord—epilepsy syndrome	0.000307	0.00723	CbGeAlD
Regorafenib—EPHX2—cerebellum—epilepsy syndrome	0.000305	0.0072	CbGeAlD
Regorafenib—FLT1—medulla oblongata—epilepsy syndrome	0.000303	0.00714	CbGeAlD
Regorafenib—RAF1—medulla oblongata—epilepsy syndrome	0.000301	0.00709	CbGeAlD
Regorafenib—FGFR2—spinal cord—epilepsy syndrome	0.000291	0.00686	CbGeAlD
Regorafenib—KIT—telencephalon—epilepsy syndrome	0.000289	0.0068	CbGeAlD
Regorafenib—Sorafenib—ABCG2—epilepsy syndrome	0.000287	0.106	CrCbGaD
Regorafenib—TEK—midbrain—epilepsy syndrome	0.000286	0.00675	CbGeAlD
Regorafenib—ABL1—brainstem—epilepsy syndrome	0.000283	0.00667	CbGeAlD
Regorafenib—PDGFRB—telencephalon—epilepsy syndrome	0.000282	0.00665	CbGeAlD
Regorafenib—TEK—spinal cord—epilepsy syndrome	0.000279	0.00658	CbGeAlD
Regorafenib—FLT1—midbrain—epilepsy syndrome	0.000277	0.00652	CbGeAlD
Regorafenib—RAF1—midbrain—epilepsy syndrome	0.000275	0.00648	CbGeAlD
Regorafenib—RET—head—epilepsy syndrome	0.000273	0.00642	CbGeAlD
Regorafenib—FGFR1—cerebellum—epilepsy syndrome	0.000272	0.0064	CbGeAlD
Regorafenib—FLT1—spinal cord—epilepsy syndrome	0.00027	0.00636	CbGeAlD
Regorafenib—RAF1—spinal cord—epilepsy syndrome	0.000268	0.00633	CbGeAlD
Regorafenib—BRAF—brain—epilepsy syndrome	0.00026	0.00612	CbGeAlD
Regorafenib—FGFR2—head—epilepsy syndrome	0.000259	0.0061	CbGeAlD
Regorafenib—RET—nervous system—epilepsy syndrome	0.000258	0.00609	CbGeAlD
Regorafenib—KDR—medulla oblongata—epilepsy syndrome	0.000256	0.00603	CbGeAlD
Regorafenib—EPHA2—head—epilepsy syndrome	0.000254	0.006	CbGeAlD
Regorafenib—PDGFRA—spinal cord—epilepsy syndrome	0.000253	0.00596	CbGeAlD
Regorafenib—ABL1—telencephalon—epilepsy syndrome	0.000251	0.00592	CbGeAlD
Regorafenib—RET—central nervous system—epilepsy syndrome	0.000249	0.00586	CbGeAlD
Regorafenib—TEK—head—epilepsy syndrome	0.000248	0.00585	CbGeAlD
Regorafenib—EPHX2—brain—epilepsy syndrome	0.000248	0.00584	CbGeAlD
Regorafenib—FGFR2—nervous system—epilepsy syndrome	0.000245	0.00578	CbGeAlD
Regorafenib—RET—cerebellum—epilepsy syndrome	0.000243	0.00573	CbGeAlD
Regorafenib—EPHA2—nervous system—epilepsy syndrome	0.000241	0.00568	CbGeAlD
Regorafenib—FLT1—head—epilepsy syndrome	0.00024	0.00566	CbGeAlD
Regorafenib—RAF1—head—epilepsy syndrome	0.000239	0.00562	CbGeAlD
Regorafenib—FGFR2—central nervous system—epilepsy syndrome	0.000236	0.00557	CbGeAlD
Regorafenib—TEK—nervous system—epilepsy syndrome	0.000235	0.00555	CbGeAlD
Regorafenib—KDR—midbrain—epilepsy syndrome	0.000234	0.00551	CbGeAlD
Regorafenib—EPHA2—central nervous system—epilepsy syndrome	0.000232	0.00547	CbGeAlD
Regorafenib—FGFR2—cerebellum—epilepsy syndrome	0.000231	0.00544	CbGeAlD
Regorafenib—KDR—spinal cord—epilepsy syndrome	0.000228	0.00538	CbGeAlD
Regorafenib—FLT1—nervous system—epilepsy syndrome	0.000228	0.00536	CbGeAlD
Regorafenib—KIT—medulla oblongata—epilepsy syndrome	0.000227	0.00535	CbGeAlD
Regorafenib—TEK—central nervous system—epilepsy syndrome	0.000227	0.00534	CbGeAlD
Regorafenib—RAF1—nervous system—epilepsy syndrome	0.000226	0.00533	CbGeAlD
Regorafenib—Sorafenib—CYP2C19—epilepsy syndrome	0.000226	0.083	CrCbGaD
Regorafenib—PDGFRA—head—epilepsy syndrome	0.000225	0.0053	CbGeAlD
Regorafenib—FLT4—brain—epilepsy syndrome	0.000224	0.00527	CbGeAlD
Regorafenib—PDGFRB—medulla oblongata—epilepsy syndrome	0.000222	0.00522	CbGeAlD
Regorafenib—TEK—cerebellum—epilepsy syndrome	0.000221	0.00522	CbGeAlD
Regorafenib—FGFR1—brain—epilepsy syndrome	0.000221	0.0052	CbGeAlD
Regorafenib—FLT1—central nervous system—epilepsy syndrome	0.000219	0.00516	CbGeAlD
Regorafenib—RAF1—central nervous system—epilepsy syndrome	0.000218	0.00513	CbGeAlD
Regorafenib—FLT1—cerebellum—epilepsy syndrome	0.000214	0.00505	CbGeAlD
Regorafenib—PDGFRA—nervous system—epilepsy syndrome	0.000213	0.00502	CbGeAlD
Regorafenib—RAF1—cerebellum—epilepsy syndrome	0.000213	0.00502	CbGeAlD
Regorafenib—KIT—midbrain—epilepsy syndrome	0.000207	0.00489	CbGeAlD
Regorafenib—PDGFRA—central nervous system—epilepsy syndrome	0.000205	0.00484	CbGeAlD
Regorafenib—KDR—head—epilepsy syndrome	0.000203	0.00478	CbGeAlD
Regorafenib—PDGFRB—midbrain—epilepsy syndrome	0.000203	0.00477	CbGeAlD
Regorafenib—KIT—spinal cord—epilepsy syndrome	0.000202	0.00477	CbGeAlD
Regorafenib—PDGFRA—cerebellum—epilepsy syndrome	0.000201	0.00473	CbGeAlD
Regorafenib—PDGFRB—spinal cord—epilepsy syndrome	0.000198	0.00466	CbGeAlD
Regorafenib—ABL1—medulla oblongata—epilepsy syndrome	0.000197	0.00465	CbGeAlD
Regorafenib—RET—brain—epilepsy syndrome	0.000197	0.00465	CbGeAlD
Regorafenib—KDR—nervous system—epilepsy syndrome	0.000192	0.00453	CbGeAlD
Regorafenib—FGFR2—brain—epilepsy syndrome	0.000188	0.00442	CbGeAlD
Regorafenib—KDR—central nervous system—epilepsy syndrome	0.000185	0.00436	CbGeAlD
Regorafenib—EPHA2—brain—epilepsy syndrome	0.000184	0.00435	CbGeAlD
Regorafenib—KDR—cerebellum—epilepsy syndrome	0.000181	0.00427	CbGeAlD
Regorafenib—ABL1—midbrain—epilepsy syndrome	0.000181	0.00425	CbGeAlD
Regorafenib—TEK—brain—epilepsy syndrome	0.00018	0.00424	CbGeAlD
Regorafenib—KIT—head—epilepsy syndrome	0.00018	0.00424	CbGeAlD
Regorafenib—ABL1—spinal cord—epilepsy syndrome	0.000176	0.00415	CbGeAlD
Regorafenib—PDGFRB—head—epilepsy syndrome	0.000176	0.00414	CbGeAlD
Regorafenib—FLT1—brain—epilepsy syndrome	0.000174	0.0041	CbGeAlD
Regorafenib—RAF1—brain—epilepsy syndrome	0.000173	0.00407	CbGeAlD
Regorafenib—KIT—nervous system—epilepsy syndrome	0.00017	0.00402	CbGeAlD
Regorafenib—Sorafenib—CYP2D6—epilepsy syndrome	0.000167	0.0615	CrCbGaD
Regorafenib—PDGFRB—nervous system—epilepsy syndrome	0.000166	0.00392	CbGeAlD
Regorafenib—KIT—central nervous system—epilepsy syndrome	0.000164	0.00387	CbGeAlD
Regorafenib—PDGFRA—brain—epilepsy syndrome	0.000163	0.00384	CbGeAlD
Regorafenib—KIT—cerebellum—epilepsy syndrome	0.00016	0.00378	CbGeAlD
Regorafenib—PDGFRB—central nervous system—epilepsy syndrome	0.00016	0.00378	CbGeAlD
Regorafenib—ABCG2—telencephalon—epilepsy syndrome	0.000159	0.00373	CbGeAlD
Regorafenib—PDGFRB—cerebellum—epilepsy syndrome	0.000157	0.00369	CbGeAlD
Regorafenib—ABL1—head—epilepsy syndrome	0.000157	0.00369	CbGeAlD
Regorafenib—ABL1—nervous system—epilepsy syndrome	0.000148	0.0035	CbGeAlD
Regorafenib—KDR—brain—epilepsy syndrome	0.000147	0.00346	CbGeAlD
Regorafenib—ABL1—central nervous system—epilepsy syndrome	0.000143	0.00337	CbGeAlD
Regorafenib—ABL1—cerebellum—epilepsy syndrome	0.00014	0.00329	CbGeAlD
Regorafenib—KIT—brain—epilepsy syndrome	0.00013	0.00307	CbGeAlD
Regorafenib—PDGFRB—brain—epilepsy syndrome	0.000127	0.003	CbGeAlD
Regorafenib—ABCG2—medulla oblongata—epilepsy syndrome	0.000125	0.00293	CbGeAlD
Regorafenib—Sorafenib—ABCB1—epilepsy syndrome	0.00012	0.0439	CrCbGaD
Regorafenib—ABCG2—midbrain—epilepsy syndrome	0.000114	0.00268	CbGeAlD
Regorafenib—ABL1—brain—epilepsy syndrome	0.000113	0.00267	CbGeAlD
Regorafenib—ABCG2—spinal cord—epilepsy syndrome	0.000111	0.00262	CbGeAlD
Regorafenib—CYP2B6—head—epilepsy syndrome	9.11e-05	0.00215	CbGeAlD
Regorafenib—ABCG2—cerebellum—epilepsy syndrome	8.81e-05	0.00207	CbGeAlD
Regorafenib—CYP2B6—nervous system—epilepsy syndrome	8.63e-05	0.00203	CbGeAlD
Regorafenib—ABCB1—forebrain—epilepsy syndrome	8.5e-05	0.002	CbGeAlD
Regorafenib—CYP2B6—central nervous system—epilepsy syndrome	8.31e-05	0.00196	CbGeAlD
Regorafenib—Decreased appetite—Oxcarbazepine—epilepsy syndrome	8e-05	0.000807	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	7.99e-05	0.000805	CcSEcCtD
Regorafenib—Fatigue—Phenytoin—epilepsy syndrome	7.98e-05	0.000804	CcSEcCtD
Regorafenib—Pain—Clonazepam—epilepsy syndrome	7.96e-05	0.000803	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	7.94e-05	0.000801	CcSEcCtD
Regorafenib—Fatigue—Oxcarbazepine—epilepsy syndrome	7.93e-05	0.0008	CcSEcCtD
Regorafenib—Haemorrhage—Gabapentin—epilepsy syndrome	7.91e-05	0.000798	CcSEcCtD
Regorafenib—Gastrointestinal pain—Zonisamide—epilepsy syndrome	7.9e-05	0.000797	CcSEcCtD
Regorafenib—Asthenia—Levetiracetam—epilepsy syndrome	7.9e-05	0.000797	CcSEcCtD
Regorafenib—Pain—Oxcarbazepine—epilepsy syndrome	7.87e-05	0.000794	CcSEcCtD
Regorafenib—Angiopathy—Pregabalin—epilepsy syndrome	7.83e-05	0.00079	CcSEcCtD
Regorafenib—ABCB1—telencephalon—epilepsy syndrome	7.82e-05	0.00184	CbGeAlD
Regorafenib—Urinary tract disorder—Gabapentin—epilepsy syndrome	7.81e-05	0.000788	CcSEcCtD
Regorafenib—Body temperature increased—Felbamate—epilepsy syndrome	7.8e-05	0.000787	CcSEcCtD
Regorafenib—Abdominal pain—Felbamate—epilepsy syndrome	7.8e-05	0.000787	CcSEcCtD
Regorafenib—Vomiting—Acetazolamide—epilepsy syndrome	7.8e-05	0.000787	CcSEcCtD
Regorafenib—Diarrhoea—Propofol—epilepsy syndrome	7.8e-05	0.000787	CcSEcCtD
Regorafenib—Tremor—Valproic Acid—epilepsy syndrome	7.78e-05	0.000785	CcSEcCtD
Regorafenib—Neutropenia—Topiramate—epilepsy syndrome	7.78e-05	0.000784	CcSEcCtD
Regorafenib—Mediastinal disorder—Pregabalin—epilepsy syndrome	7.78e-05	0.000784	CcSEcCtD
Regorafenib—Connective tissue disorder—Gabapentin—epilepsy syndrome	7.78e-05	0.000784	CcSEcCtD
Regorafenib—Urethral disorder—Gabapentin—epilepsy syndrome	7.76e-05	0.000782	CcSEcCtD
Regorafenib—Headache—Acetazolamide—epilepsy syndrome	7.69e-05	0.000775	CcSEcCtD
Regorafenib—Anaemia—Valproic Acid—epilepsy syndrome	7.68e-05	0.000775	CcSEcCtD
Regorafenib—Decreased appetite—Carbamazepine—epilepsy syndrome	7.68e-05	0.000774	CcSEcCtD
Regorafenib—Body temperature increased—Zonisamide—epilepsy syndrome	7.64e-05	0.00077	CcSEcCtD
Regorafenib—Abdominal pain—Zonisamide—epilepsy syndrome	7.64e-05	0.00077	CcSEcCtD
Regorafenib—Asthenia—Fosphenytoin—epilepsy syndrome	7.63e-05	0.000769	CcSEcCtD
Regorafenib—Alopecia—Pregabalin—epilepsy syndrome	7.63e-05	0.000769	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	7.62e-05	0.000769	CcSEcCtD
Regorafenib—Gastrointestinal pain—Clonazepam—epilepsy syndrome	7.62e-05	0.000768	CcSEcCtD
Regorafenib—Fatigue—Carbamazepine—epilepsy syndrome	7.61e-05	0.000768	CcSEcCtD
Regorafenib—Pain—Carbamazepine—epilepsy syndrome	7.55e-05	0.000762	CcSEcCtD
Regorafenib—Diarrhoea—Levetiracetam—epilepsy syndrome	7.54e-05	0.00076	CcSEcCtD
Regorafenib—Weight decreased—Topiramate—epilepsy syndrome	7.52e-05	0.000759	CcSEcCtD
Regorafenib—Gastrointestinal pain—Oxcarbazepine—epilepsy syndrome	7.52e-05	0.000759	CcSEcCtD
Regorafenib—Malnutrition—Pregabalin—epilepsy syndrome	7.51e-05	0.000758	CcSEcCtD
Regorafenib—Erythema multiforme—Gabapentin—epilepsy syndrome	7.48e-05	0.000755	CcSEcCtD
Regorafenib—Leukopenia—Valproic Acid—epilepsy syndrome	7.44e-05	0.00075	CcSEcCtD
Regorafenib—Asthenia—Vigabatrin—epilepsy syndrome	7.43e-05	0.00075	CcSEcCtD
Regorafenib—Decreased appetite—Lamotrigine—epilepsy syndrome	7.42e-05	0.000748	CcSEcCtD
Regorafenib—Infestation—Topiramate—epilepsy syndrome	7.42e-05	0.000748	CcSEcCtD
Regorafenib—Infestation NOS—Topiramate—epilepsy syndrome	7.42e-05	0.000748	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	7.37e-05	0.000743	CcSEcCtD
Regorafenib—Body temperature increased—Clonazepam—epilepsy syndrome	7.36e-05	0.000743	CcSEcCtD
Regorafenib—Abdominal pain—Clonazepam—epilepsy syndrome	7.36e-05	0.000743	CcSEcCtD
Regorafenib—Fatigue—Lamotrigine—epilepsy syndrome	7.36e-05	0.000742	CcSEcCtD
Regorafenib—CYP2C8—brain—epilepsy syndrome	7.36e-05	0.00173	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Topiramate—epilepsy syndrome	7.35e-05	0.000742	CcSEcCtD
Regorafenib—Cardiac disorder—Gabapentin—epilepsy syndrome	7.34e-05	0.000741	CcSEcCtD
Regorafenib—Asthenia—Diazepam—epilepsy syndrome	7.32e-05	0.000738	CcSEcCtD
Regorafenib—Body temperature increased—Phenytoin—epilepsy syndrome	7.31e-05	0.000738	CcSEcCtD
Regorafenib—Pain—Lamotrigine—epilepsy syndrome	7.3e-05	0.000736	CcSEcCtD
Regorafenib—Nausea—Acetazolamide—epilepsy syndrome	7.29e-05	0.000735	CcSEcCtD
Regorafenib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	7.27e-05	0.000734	CcSEcCtD
Regorafenib—Abdominal pain—Oxcarbazepine—epilepsy syndrome	7.27e-05	0.000734	CcSEcCtD
Regorafenib—Diarrhoea—Fosphenytoin—epilepsy syndrome	7.27e-05	0.000733	CcSEcCtD
Regorafenib—Vomiting—Propofol—epilepsy syndrome	7.25e-05	0.000731	CcSEcCtD
Regorafenib—Stomatitis—Topiramate—epilepsy syndrome	7.23e-05	0.000729	CcSEcCtD
Regorafenib—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	7.22e-05	0.000728	CcSEcCtD
Regorafenib—Rash—Propofol—epilepsy syndrome	7.19e-05	0.000725	CcSEcCtD
Regorafenib—Dermatitis—Propofol—epilepsy syndrome	7.18e-05	0.000724	CcSEcCtD
Regorafenib—Hypertension—Valproic Acid—epilepsy syndrome	7.17e-05	0.000724	CcSEcCtD
Regorafenib—ABCG2—brain—epilepsy syndrome	7.15e-05	0.00169	CbGeAlD
Regorafenib—Headache—Propofol—epilepsy syndrome	7.14e-05	0.00072	CcSEcCtD
Regorafenib—Mediastinal disorder—Gabapentin—epilepsy syndrome	7.13e-05	0.000719	CcSEcCtD
Regorafenib—Vomiting—Midazolam—epilepsy syndrome	7.09e-05	0.000715	CcSEcCtD
Regorafenib—Diarrhoea—Vigabatrin—epilepsy syndrome	7.09e-05	0.000715	CcSEcCtD
Regorafenib—Asthenia—Felbamate—epilepsy syndrome	7.08e-05	0.000714	CcSEcCtD
Regorafenib—Tremor—Pregabalin—epilepsy syndrome	7.04e-05	0.00071	CcSEcCtD
Regorafenib—Rash—Midazolam—epilepsy syndrome	7.03e-05	0.000709	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	7.03e-05	0.000709	CcSEcCtD
Regorafenib—Dermatitis—Midazolam—epilepsy syndrome	7.03e-05	0.000709	CcSEcCtD
Regorafenib—Vomiting—Levetiracetam—epilepsy syndrome	7e-05	0.000706	CcSEcCtD
Regorafenib—Alopecia—Gabapentin—epilepsy syndrome	6.99e-05	0.000705	CcSEcCtD
Regorafenib—Headache—Midazolam—epilepsy syndrome	6.99e-05	0.000705	CcSEcCtD
Regorafenib—Body temperature increased—Carbamazepine—epilepsy syndrome	6.98e-05	0.000704	CcSEcCtD
Regorafenib—Abdominal pain—Carbamazepine—epilepsy syndrome	6.98e-05	0.000704	CcSEcCtD
Regorafenib—Diarrhoea—Diazepam—epilepsy syndrome	6.98e-05	0.000704	CcSEcCtD
Regorafenib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	6.98e-05	0.000704	CcSEcCtD
Regorafenib—Rash—Levetiracetam—epilepsy syndrome	6.94e-05	0.0007	CcSEcCtD
Regorafenib—Anaemia—Pregabalin—epilepsy syndrome	6.94e-05	0.0007	CcSEcCtD
Regorafenib—Dermatitis—Levetiracetam—epilepsy syndrome	6.94e-05	0.0007	CcSEcCtD
Regorafenib—Asthenia—Zonisamide—epilepsy syndrome	6.93e-05	0.000699	CcSEcCtD
Regorafenib—Dry mouth—Valproic Acid—epilepsy syndrome	6.92e-05	0.000698	CcSEcCtD
Regorafenib—Headache—Levetiracetam—epilepsy syndrome	6.9e-05	0.000696	CcSEcCtD
Regorafenib—Malnutrition—Gabapentin—epilepsy syndrome	6.89e-05	0.000695	CcSEcCtD
Regorafenib—Nausea—Propofol—epilepsy syndrome	6.77e-05	0.000683	CcSEcCtD
Regorafenib—Vomiting—Fosphenytoin—epilepsy syndrome	6.76e-05	0.000682	CcSEcCtD
Regorafenib—Diarrhoea—Felbamate—epilepsy syndrome	6.75e-05	0.000681	CcSEcCtD
Regorafenib—Abdominal pain—Lamotrigine—epilepsy syndrome	6.75e-05	0.00068	CcSEcCtD
Regorafenib—Body temperature increased—Lamotrigine—epilepsy syndrome	6.75e-05	0.00068	CcSEcCtD
Regorafenib—Infection—Valproic Acid—epilepsy syndrome	6.74e-05	0.000679	CcSEcCtD
Regorafenib—Leukopenia—Pregabalin—epilepsy syndrome	6.72e-05	0.000678	CcSEcCtD
Regorafenib—Rash—Fosphenytoin—epilepsy syndrome	6.7e-05	0.000676	CcSEcCtD
Regorafenib—Dermatitis—Fosphenytoin—epilepsy syndrome	6.7e-05	0.000675	CcSEcCtD
Regorafenib—Haemoglobin—Topiramate—epilepsy syndrome	6.69e-05	0.000675	CcSEcCtD
Regorafenib—Asthenia—Clonazepam—epilepsy syndrome	6.68e-05	0.000674	CcSEcCtD
Regorafenib—Headache—Fosphenytoin—epilepsy syndrome	6.66e-05	0.000672	CcSEcCtD
Regorafenib—Haemorrhage—Topiramate—epilepsy syndrome	6.66e-05	0.000671	CcSEcCtD
Regorafenib—Nervous system disorder—Valproic Acid—epilepsy syndrome	6.65e-05	0.000671	CcSEcCtD
Regorafenib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	6.64e-05	0.00067	CcSEcCtD
Regorafenib—Asthenia—Phenytoin—epilepsy syndrome	6.64e-05	0.000669	CcSEcCtD
Regorafenib—Nausea—Midazolam—epilepsy syndrome	6.62e-05	0.000668	CcSEcCtD
Regorafenib—Diarrhoea—Zonisamide—epilepsy syndrome	6.61e-05	0.000667	CcSEcCtD
Regorafenib—Asthenia—Oxcarbazepine—epilepsy syndrome	6.6e-05	0.000666	CcSEcCtD
Regorafenib—CYP2B6—brain—epilepsy syndrome	6.6e-05	0.00155	CbGeAlD
Regorafenib—Vomiting—Vigabatrin—epilepsy syndrome	6.59e-05	0.000664	CcSEcCtD
Regorafenib—Skin disorder—Valproic Acid—epilepsy syndrome	6.59e-05	0.000664	CcSEcCtD
Regorafenib—Urinary tract disorder—Topiramate—epilepsy syndrome	6.57e-05	0.000663	CcSEcCtD
Regorafenib—Connective tissue disorder—Topiramate—epilepsy syndrome	6.54e-05	0.00066	CcSEcCtD
Regorafenib—Nausea—Levetiracetam—epilepsy syndrome	6.54e-05	0.00066	CcSEcCtD
Regorafenib—Rash—Vigabatrin—epilepsy syndrome	6.53e-05	0.000659	CcSEcCtD
Regorafenib—Dermatitis—Vigabatrin—epilepsy syndrome	6.53e-05	0.000658	CcSEcCtD
Regorafenib—Urethral disorder—Topiramate—epilepsy syndrome	6.53e-05	0.000658	CcSEcCtD
Regorafenib—CYP3A4—nervous system—epilepsy syndrome	6.52e-05	0.00154	CbGeAlD
Regorafenib—Headache—Vigabatrin—epilepsy syndrome	6.49e-05	0.000655	CcSEcCtD
Regorafenib—Hypertension—Pregabalin—epilepsy syndrome	6.49e-05	0.000654	CcSEcCtD
Regorafenib—Vomiting—Diazepam—epilepsy syndrome	6.49e-05	0.000654	CcSEcCtD
Regorafenib—Tremor—Gabapentin—epilepsy syndrome	6.45e-05	0.000651	CcSEcCtD
Regorafenib—Rash—Diazepam—epilepsy syndrome	6.43e-05	0.000649	CcSEcCtD
Regorafenib—Dermatitis—Diazepam—epilepsy syndrome	6.43e-05	0.000648	CcSEcCtD
Regorafenib—Headache—Diazepam—epilepsy syndrome	6.39e-05	0.000644	CcSEcCtD
Regorafenib—Diarrhoea—Clonazepam—epilepsy syndrome	6.37e-05	0.000643	CcSEcCtD
Regorafenib—Anaemia—Gabapentin—epilepsy syndrome	6.37e-05	0.000642	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	6.35e-05	0.000641	CcSEcCtD
Regorafenib—Asthenia—Carbamazepine—epilepsy syndrome	6.34e-05	0.000639	CcSEcCtD
Regorafenib—Diarrhoea—Phenytoin—epilepsy syndrome	6.33e-05	0.000638	CcSEcCtD
Regorafenib—Nausea—Fosphenytoin—epilepsy syndrome	6.31e-05	0.000637	CcSEcCtD
Regorafenib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	6.3e-05	0.000635	CcSEcCtD
Regorafenib—Erythema multiforme—Topiramate—epilepsy syndrome	6.29e-05	0.000635	CcSEcCtD
Regorafenib—Vomiting—Felbamate—epilepsy syndrome	6.28e-05	0.000633	CcSEcCtD
Regorafenib—CYP3A4—central nervous system—epilepsy syndrome	6.28e-05	0.00148	CbGeAlD
Regorafenib—Dry mouth—Pregabalin—epilepsy syndrome	6.25e-05	0.000631	CcSEcCtD
Regorafenib—Rash—Felbamate—epilepsy syndrome	6.22e-05	0.000628	CcSEcCtD
Regorafenib—Dermatitis—Felbamate—epilepsy syndrome	6.22e-05	0.000627	CcSEcCtD
Regorafenib—Headache—Felbamate—epilepsy syndrome	6.18e-05	0.000624	CcSEcCtD
Regorafenib—Cardiac disorder—Topiramate—epilepsy syndrome	6.18e-05	0.000623	CcSEcCtD
Regorafenib—Leukopenia—Gabapentin—epilepsy syndrome	6.17e-05	0.000622	CcSEcCtD
Regorafenib—Nausea—Vigabatrin—epilepsy syndrome	6.15e-05	0.000621	CcSEcCtD
Regorafenib—Vomiting—Zonisamide—epilepsy syndrome	6.14e-05	0.00062	CcSEcCtD
Regorafenib—ABCB1—medulla oblongata—epilepsy syndrome	6.14e-05	0.00145	CbGeAlD
Regorafenib—Asthenia—Lamotrigine—epilepsy syndrome	6.12e-05	0.000618	CcSEcCtD
Regorafenib—Rash—Zonisamide—epilepsy syndrome	6.09e-05	0.000615	CcSEcCtD
Regorafenib—Infection—Pregabalin—epilepsy syndrome	6.09e-05	0.000614	CcSEcCtD
Regorafenib—Dermatitis—Zonisamide—epilepsy syndrome	6.09e-05	0.000614	CcSEcCtD
Regorafenib—Nausea—Diazepam—epilepsy syndrome	6.06e-05	0.000611	CcSEcCtD
Regorafenib—Headache—Zonisamide—epilepsy syndrome	6.05e-05	0.000611	CcSEcCtD
Regorafenib—Diarrhoea—Carbamazepine—epilepsy syndrome	6.04e-05	0.000609	CcSEcCtD
Regorafenib—Angiopathy—Topiramate—epilepsy syndrome	6.04e-05	0.000609	CcSEcCtD
Regorafenib—Nervous system disorder—Pregabalin—epilepsy syndrome	6.01e-05	0.000606	CcSEcCtD
Regorafenib—Thrombocytopenia—Pregabalin—epilepsy syndrome	6e-05	0.000605	CcSEcCtD
Regorafenib—Mediastinal disorder—Topiramate—epilepsy syndrome	6e-05	0.000605	CcSEcCtD
Regorafenib—Skin disorder—Pregabalin—epilepsy syndrome	5.96e-05	0.000601	CcSEcCtD
Regorafenib—Hypertension—Gabapentin—epilepsy syndrome	5.95e-05	0.0006	CcSEcCtD
Regorafenib—Vomiting—Clonazepam—epilepsy syndrome	5.92e-05	0.000597	CcSEcCtD
Regorafenib—Decreased appetite—Valproic Acid—epilepsy syndrome	5.9e-05	0.000595	CcSEcCtD
Regorafenib—Alopecia—Topiramate—epilepsy syndrome	5.88e-05	0.000593	CcSEcCtD
Regorafenib—Vomiting—Phenytoin—epilepsy syndrome	5.88e-05	0.000593	CcSEcCtD
Regorafenib—Rash—Clonazepam—epilepsy syndrome	5.87e-05	0.000592	CcSEcCtD
Regorafenib—Dermatitis—Clonazepam—epilepsy syndrome	5.87e-05	0.000592	CcSEcCtD
Regorafenib—Nausea—Felbamate—epilepsy syndrome	5.86e-05	0.000591	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	5.85e-05	0.00059	CcSEcCtD
Regorafenib—Vomiting—Oxcarbazepine—epilepsy syndrome	5.85e-05	0.00059	CcSEcCtD
Regorafenib—Fatigue—Valproic Acid—epilepsy syndrome	5.85e-05	0.00059	CcSEcCtD
Regorafenib—Diarrhoea—Lamotrigine—epilepsy syndrome	5.84e-05	0.000589	CcSEcCtD
Regorafenib—Headache—Clonazepam—epilepsy syndrome	5.83e-05	0.000588	CcSEcCtD
Regorafenib—Rash—Phenytoin—epilepsy syndrome	5.83e-05	0.000588	CcSEcCtD
Regorafenib—Dermatitis—Phenytoin—epilepsy syndrome	5.83e-05	0.000588	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	5.82e-05	0.000587	CcSEcCtD
Regorafenib—Rash—Oxcarbazepine—epilepsy syndrome	5.8e-05	0.000585	CcSEcCtD
Regorafenib—Pain—Valproic Acid—epilepsy syndrome	5.8e-05	0.000585	CcSEcCtD
Regorafenib—Dermatitis—Oxcarbazepine—epilepsy syndrome	5.8e-05	0.000585	CcSEcCtD
Regorafenib—Headache—Phenytoin—epilepsy syndrome	5.8e-05	0.000584	CcSEcCtD
Regorafenib—Malnutrition—Topiramate—epilepsy syndrome	5.8e-05	0.000584	CcSEcCtD
Regorafenib—Headache—Oxcarbazepine—epilepsy syndrome	5.76e-05	0.000581	CcSEcCtD
Regorafenib—Nausea—Zonisamide—epilepsy syndrome	5.74e-05	0.000579	CcSEcCtD
Regorafenib—Dry mouth—Gabapentin—epilepsy syndrome	5.74e-05	0.000578	CcSEcCtD
Regorafenib—Vomiting—Carbamazepine—epilepsy syndrome	5.61e-05	0.000566	CcSEcCtD
Regorafenib—ABCB1—midbrain—epilepsy syndrome	5.61e-05	0.00132	CbGeAlD
Regorafenib—Infection—Gabapentin—epilepsy syndrome	5.59e-05	0.000563	CcSEcCtD
Regorafenib—Rash—Carbamazepine—epilepsy syndrome	5.57e-05	0.000562	CcSEcCtD
Regorafenib—Dermatitis—Carbamazepine—epilepsy syndrome	5.56e-05	0.000561	CcSEcCtD
Regorafenib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	5.55e-05	0.000559	CcSEcCtD
Regorafenib—Nausea—Clonazepam—epilepsy syndrome	5.53e-05	0.000558	CcSEcCtD
Regorafenib—Headache—Carbamazepine—epilepsy syndrome	5.53e-05	0.000558	CcSEcCtD
Regorafenib—Nervous system disorder—Gabapentin—epilepsy syndrome	5.51e-05	0.000556	CcSEcCtD
Regorafenib—Thrombocytopenia—Gabapentin—epilepsy syndrome	5.5e-05	0.000555	CcSEcCtD
Regorafenib—Nausea—Phenytoin—epilepsy syndrome	5.49e-05	0.000554	CcSEcCtD
Regorafenib—ABCB1—spinal cord—epilepsy syndrome	5.48e-05	0.00129	CbGeAlD
Regorafenib—Nausea—Oxcarbazepine—epilepsy syndrome	5.47e-05	0.000551	CcSEcCtD
Regorafenib—Skin disorder—Gabapentin—epilepsy syndrome	5.46e-05	0.000551	CcSEcCtD
Regorafenib—Tremor—Topiramate—epilepsy syndrome	5.43e-05	0.000548	CcSEcCtD
Regorafenib—Vomiting—Lamotrigine—epilepsy syndrome	5.43e-05	0.000547	CcSEcCtD
Regorafenib—Rash—Lamotrigine—epilepsy syndrome	5.38e-05	0.000543	CcSEcCtD
Regorafenib—Dermatitis—Lamotrigine—epilepsy syndrome	5.38e-05	0.000542	CcSEcCtD
Regorafenib—Body temperature increased—Valproic Acid—epilepsy syndrome	5.36e-05	0.000541	CcSEcCtD
Regorafenib—Abdominal pain—Valproic Acid—epilepsy syndrome	5.36e-05	0.000541	CcSEcCtD
Regorafenib—Anaemia—Topiramate—epilepsy syndrome	5.36e-05	0.00054	CcSEcCtD
Regorafenib—Headache—Lamotrigine—epilepsy syndrome	5.35e-05	0.000539	CcSEcCtD
Regorafenib—Decreased appetite—Pregabalin—epilepsy syndrome	5.33e-05	0.000538	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	5.29e-05	0.000534	CcSEcCtD
Regorafenib—Fatigue—Pregabalin—epilepsy syndrome	5.29e-05	0.000533	CcSEcCtD
Regorafenib—Nausea—Carbamazepine—epilepsy syndrome	5.25e-05	0.000529	CcSEcCtD
Regorafenib—Pain—Pregabalin—epilepsy syndrome	5.24e-05	0.000529	CcSEcCtD
Regorafenib—Leukopenia—Topiramate—epilepsy syndrome	5.19e-05	0.000523	CcSEcCtD
Regorafenib—Nausea—Lamotrigine—epilepsy syndrome	5.07e-05	0.000511	CcSEcCtD
Regorafenib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	5.01e-05	0.000506	CcSEcCtD
Regorafenib—Hypertension—Topiramate—epilepsy syndrome	5e-05	0.000505	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	4.9e-05	0.000494	CcSEcCtD
Regorafenib—Decreased appetite—Gabapentin—epilepsy syndrome	4.89e-05	0.000493	CcSEcCtD
Regorafenib—ABCB1—head—epilepsy syndrome	4.87e-05	0.00115	CbGeAlD
Regorafenib—Asthenia—Valproic Acid—epilepsy syndrome	4.87e-05	0.000491	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	4.85e-05	0.00049	CcSEcCtD
Regorafenib—Fatigue—Gabapentin—epilepsy syndrome	4.85e-05	0.000489	CcSEcCtD
Regorafenib—Abdominal pain—Pregabalin—epilepsy syndrome	4.85e-05	0.000489	CcSEcCtD
Regorafenib—Body temperature increased—Pregabalin—epilepsy syndrome	4.85e-05	0.000489	CcSEcCtD
Regorafenib—Dry mouth—Topiramate—epilepsy syndrome	4.83e-05	0.000487	CcSEcCtD
Regorafenib—Pain—Gabapentin—epilepsy syndrome	4.81e-05	0.000485	CcSEcCtD
Regorafenib—Infection—Topiramate—epilepsy syndrome	4.7e-05	0.000474	CcSEcCtD
Regorafenib—Diarrhoea—Valproic Acid—epilepsy syndrome	4.64e-05	0.000468	CcSEcCtD
Regorafenib—Nervous system disorder—Topiramate—epilepsy syndrome	4.64e-05	0.000468	CcSEcCtD
Regorafenib—Thrombocytopenia—Topiramate—epilepsy syndrome	4.63e-05	0.000467	CcSEcCtD
Regorafenib—ABCB1—nervous system—epilepsy syndrome	4.61e-05	0.00109	CbGeAlD
Regorafenib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	4.6e-05	0.000464	CcSEcCtD
Regorafenib—Skin disorder—Topiramate—epilepsy syndrome	4.59e-05	0.000463	CcSEcCtD
Regorafenib—Abdominal pain—Gabapentin—epilepsy syndrome	4.44e-05	0.000448	CcSEcCtD
Regorafenib—Body temperature increased—Gabapentin—epilepsy syndrome	4.44e-05	0.000448	CcSEcCtD
Regorafenib—ABCB1—central nervous system—epilepsy syndrome	4.44e-05	0.00105	CbGeAlD
Regorafenib—Asthenia—Pregabalin—epilepsy syndrome	4.4e-05	0.000444	CcSEcCtD
Regorafenib—ABCB1—cerebellum—epilepsy syndrome	4.34e-05	0.00102	CbGeAlD
Regorafenib—Vomiting—Valproic Acid—epilepsy syndrome	4.31e-05	0.000435	CcSEcCtD
Regorafenib—Rash—Valproic Acid—epilepsy syndrome	4.28e-05	0.000431	CcSEcCtD
Regorafenib—Dermatitis—Valproic Acid—epilepsy syndrome	4.27e-05	0.000431	CcSEcCtD
Regorafenib—Headache—Valproic Acid—epilepsy syndrome	4.25e-05	0.000428	CcSEcCtD
Regorafenib—Diarrhoea—Pregabalin—epilepsy syndrome	4.19e-05	0.000423	CcSEcCtD
Regorafenib—Decreased appetite—Topiramate—epilepsy syndrome	4.11e-05	0.000415	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	4.08e-05	0.000412	CcSEcCtD
Regorafenib—Fatigue—Topiramate—epilepsy syndrome	4.08e-05	0.000411	CcSEcCtD
Regorafenib—Pain—Topiramate—epilepsy syndrome	4.04e-05	0.000408	CcSEcCtD
Regorafenib—Asthenia—Gabapentin—epilepsy syndrome	4.03e-05	0.000407	CcSEcCtD
Regorafenib—Nausea—Valproic Acid—epilepsy syndrome	4.03e-05	0.000406	CcSEcCtD
Regorafenib—Vomiting—Pregabalin—epilepsy syndrome	3.9e-05	0.000393	CcSEcCtD
Regorafenib—Gastrointestinal pain—Topiramate—epilepsy syndrome	3.87e-05	0.00039	CcSEcCtD
Regorafenib—Rash—Pregabalin—epilepsy syndrome	3.87e-05	0.00039	CcSEcCtD
Regorafenib—Dermatitis—Pregabalin—epilepsy syndrome	3.86e-05	0.00039	CcSEcCtD
Regorafenib—Diarrhoea—Gabapentin—epilepsy syndrome	3.85e-05	0.000388	CcSEcCtD
Regorafenib—Headache—Pregabalin—epilepsy syndrome	3.84e-05	0.000387	CcSEcCtD
Regorafenib—Abdominal pain—Topiramate—epilepsy syndrome	3.74e-05	0.000377	CcSEcCtD
Regorafenib—Body temperature increased—Topiramate—epilepsy syndrome	3.74e-05	0.000377	CcSEcCtD
Regorafenib—Nausea—Pregabalin—epilepsy syndrome	3.64e-05	0.000367	CcSEcCtD
Regorafenib—Vomiting—Gabapentin—epilepsy syndrome	3.57e-05	0.000361	CcSEcCtD
Regorafenib—Rash—Gabapentin—epilepsy syndrome	3.54e-05	0.000358	CcSEcCtD
Regorafenib—Dermatitis—Gabapentin—epilepsy syndrome	3.54e-05	0.000357	CcSEcCtD
Regorafenib—ABCB1—brain—epilepsy syndrome	3.53e-05	0.000831	CbGeAlD
Regorafenib—Headache—Gabapentin—epilepsy syndrome	3.52e-05	0.000355	CcSEcCtD
Regorafenib—Asthenia—Topiramate—epilepsy syndrome	3.39e-05	0.000342	CcSEcCtD
Regorafenib—Nausea—Gabapentin—epilepsy syndrome	3.34e-05	0.000337	CcSEcCtD
Regorafenib—Diarrhoea—Topiramate—epilepsy syndrome	3.24e-05	0.000326	CcSEcCtD
Regorafenib—Vomiting—Topiramate—epilepsy syndrome	3.01e-05	0.000303	CcSEcCtD
Regorafenib—Rash—Topiramate—epilepsy syndrome	2.98e-05	0.000301	CcSEcCtD
Regorafenib—Dermatitis—Topiramate—epilepsy syndrome	2.98e-05	0.0003	CcSEcCtD
Regorafenib—Headache—Topiramate—epilepsy syndrome	2.96e-05	0.000299	CcSEcCtD
Regorafenib—Nausea—Topiramate—epilepsy syndrome	2.81e-05	0.000283	CcSEcCtD
Regorafenib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	9.61e-07	8.59e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—SRC—epilepsy syndrome	9.6e-07	8.58e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PRKCB—epilepsy syndrome	9.58e-07	8.57e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	9.57e-07	8.56e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—POMC—epilepsy syndrome	9.57e-07	8.55e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—POMC—epilepsy syndrome	9.57e-07	8.55e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6ST—epilepsy syndrome	9.54e-07	8.53e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL2—epilepsy syndrome	9.51e-07	8.5e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—JUN—epilepsy syndrome	9.49e-07	8.49e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL2—epilepsy syndrome	9.48e-07	8.48e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—JUN—epilepsy syndrome	9.46e-07	8.46e-06	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	9.46e-07	8.46e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—epilepsy syndrome	9.45e-07	8.45e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	9.43e-07	8.43e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—SRC—epilepsy syndrome	9.43e-07	8.43e-06	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—AKT1—epilepsy syndrome	9.38e-07	8.39e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	9.33e-07	8.34e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—RELA—epilepsy syndrome	9.32e-07	8.33e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	9.3e-07	8.31e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—AKT1—epilepsy syndrome	9.29e-07	8.31e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	9.27e-07	8.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TSC2—epilepsy syndrome	9.26e-07	8.27e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AGT—epilepsy syndrome	9.24e-07	8.26e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—epilepsy syndrome	9.24e-07	8.26e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—RELA—epilepsy syndrome	9.23e-07	8.25e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FGF2—epilepsy syndrome	9.22e-07	8.24e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	9.2e-07	8.23e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	9.2e-07	8.23e-06	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—AKT1—epilepsy syndrome	9.2e-07	8.23e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	9.2e-07	8.22e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	9.18e-07	8.2e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—TH—epilepsy syndrome	9.16e-07	8.19e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MTOR—epilepsy syndrome	9.14e-07	8.17e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—epilepsy syndrome	9.06e-07	8.1e-06	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	9.06e-07	8.1e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MTOR—epilepsy syndrome	9.05e-07	8.09e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FGF2—epilepsy syndrome	9.05e-07	8.09e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—HMOX1—epilepsy syndrome	9.03e-07	8.08e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	9.02e-07	8.07e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—SRC—epilepsy syndrome	9.01e-07	8.06e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	8.96e-07	8.01e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—SRC—epilepsy syndrome	8.95e-07	8e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MTOR—epilepsy syndrome	8.94e-07	8e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—epilepsy syndrome	8.93e-07	7.98e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—SRC—epilepsy syndrome	8.93e-07	7.98e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—AKT1—epilepsy syndrome	8.92e-07	7.98e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CAT—epilepsy syndrome	8.91e-07	7.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KDR—epilepsy syndrome	8.87e-07	7.93e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—epilepsy syndrome	8.86e-07	7.92e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	8.82e-07	7.89e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—epilepsy syndrome	8.78e-07	7.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	8.74e-07	7.81e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—POMC—epilepsy syndrome	8.73e-07	7.8e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—epilepsy syndrome	8.72e-07	7.8e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—epilepsy syndrome	8.72e-07	7.8e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—SRC—epilepsy syndrome	8.71e-07	7.79e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—BCHE—epilepsy syndrome	8.7e-07	7.78e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ABCB1—epilepsy syndrome	8.67e-07	7.75e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—JUN—epilepsy syndrome	8.65e-07	7.74e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FGF2—epilepsy syndrome	8.59e-07	7.68e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FGF2—epilepsy syndrome	8.57e-07	7.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	8.56e-07	7.66e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—RELA—epilepsy syndrome	8.56e-07	7.65e-06	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	8.54e-07	7.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PRKCB—epilepsy syndrome	8.54e-07	7.64e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL2—epilepsy syndrome	8.54e-07	7.64e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	8.53e-07	7.62e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—SRC—epilepsy syndrome	8.52e-07	7.61e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6ST—epilepsy syndrome	8.51e-07	7.61e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—BCHE—epilepsy syndrome	8.49e-07	7.59e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—SRC—epilepsy syndrome	8.49e-07	7.59e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP3—epilepsy syndrome	8.41e-07	7.51e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—RELA—epilepsy syndrome	8.4e-07	7.51e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	8.39e-07	7.5e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MTOR—epilepsy syndrome	8.39e-07	7.5e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	8.37e-07	7.48e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP3—epilepsy syndrome	8.33e-07	7.44e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	8.3e-07	7.42e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—epilepsy syndrome	8.29e-07	7.42e-06	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—AKT1—epilepsy syndrome	8.28e-07	7.41e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MTOR—epilepsy syndrome	8.24e-07	7.37e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	8.21e-07	7.34e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TH—epilepsy syndrome	8.18e-07	7.31e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—JUN—epilepsy syndrome	8.16e-07	7.3e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—POMC—epilepsy syndrome	8.12e-07	7.26e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	8.1e-07	7.24e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JUN—epilepsy syndrome	8.09e-07	7.23e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GPX1—epilepsy syndrome	8.06e-07	7.21e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	8.05e-07	7.2e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—SRC—epilepsy syndrome	8.04e-07	7.19e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	8.01e-07	7.16e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TH—epilepsy syndrome	7.98e-07	7.14e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—RELA—epilepsy syndrome	7.97e-07	7.13e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	7.97e-07	7.12e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—RELA—epilepsy syndrome	7.95e-07	7.11e-06	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—AKT1—epilepsy syndrome	7.95e-07	7.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—AKT1—epilepsy syndrome	7.95e-07	7.11e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—epilepsy syndrome	7.94e-07	7.1e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—BCHE—epilepsy syndrome	7.93e-07	7.09e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—epilepsy syndrome	7.87e-07	7.04e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MTOR—epilepsy syndrome	7.82e-07	6.99e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MTOR—epilepsy syndrome	7.8e-07	6.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—POMC—epilepsy syndrome	7.78e-07	6.96e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—SRC—epilepsy syndrome	7.76e-07	6.94e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	7.74e-07	6.92e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	7.74e-07	6.92e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FGF2—epilepsy syndrome	7.72e-07	6.9e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP3—epilepsy syndrome	7.72e-07	6.9e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	7.65e-07	6.84e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—epilepsy syndrome	7.63e-07	6.82e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—epilepsy syndrome	7.63e-07	6.82e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—epilepsy syndrome	7.61e-07	6.81e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP3—epilepsy syndrome	7.58e-07	6.78e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	7.57e-07	6.77e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAT—epilepsy syndrome	7.55e-07	6.75e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JUN—epilepsy syndrome	7.5e-07	6.7e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	7.48e-07	6.69e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TH—epilepsy syndrome	7.46e-07	6.67e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—epilepsy syndrome	7.4e-07	6.62e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JUN—epilepsy syndrome	7.36e-07	6.58e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	7.34e-07	6.56e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	7.34e-07	6.56e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—SRC—epilepsy syndrome	7.32e-07	6.55e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—epilepsy syndrome	7.29e-07	6.52e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—SRC—epilepsy syndrome	7.25e-07	6.49e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP3—epilepsy syndrome	7.19e-07	6.43e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP3—epilepsy syndrome	7.17e-07	6.41e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—SRC—epilepsy syndrome	7.17e-07	6.41e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RELA—epilepsy syndrome	7.17e-07	6.41e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—epilepsy syndrome	7.16e-07	6.4e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—epilepsy syndrome	7.13e-07	6.38e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AGT—epilepsy syndrome	7.07e-07	6.32e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—epilepsy syndrome	7.07e-07	6.32e-06	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—AKT1—epilepsy syndrome	7.04e-07	6.29e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MTOR—epilepsy syndrome	7.03e-07	6.28e-06	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—AKT1—epilepsy syndrome	7e-07	6.26e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—epilepsy syndrome	6.99e-07	6.25e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—epilepsy syndrome	6.97e-07	6.23e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—epilepsy syndrome	6.93e-07	6.19e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FGF2—epilepsy syndrome	6.88e-07	6.15e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	6.83e-07	6.1e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	6.82e-07	6.1e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—epilepsy syndrome	6.8e-07	6.08e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—epilepsy syndrome	6.78e-07	6.06e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAT—epilepsy syndrome	6.74e-07	6.02e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SRC—epilepsy syndrome	6.72e-07	6.01e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	6.66e-07	5.96e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SRC—epilepsy syndrome	6.6e-07	5.9e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAT—epilepsy syndrome	6.57e-07	5.88e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	6.55e-07	5.86e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—epilepsy syndrome	6.55e-07	5.85e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	6.47e-07	5.79e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—epilepsy syndrome	6.46e-07	5.78e-06	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—epilepsy syndrome	6.46e-07	5.78e-06	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—epilepsy syndrome	6.44e-07	5.76e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—epilepsy syndrome	6.43e-07	5.75e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RELA—epilepsy syndrome	6.39e-07	5.71e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—epilepsy syndrome	6.35e-07	5.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	6.31e-07	5.64e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—epilepsy syndrome	6.28e-07	5.61e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—epilepsy syndrome	6.27e-07	5.6e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—epilepsy syndrome	6.26e-07	5.6e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—epilepsy syndrome	6.25e-07	5.59e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	6.22e-07	5.57e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	6.15e-07	5.5e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAT—epilepsy syndrome	6.14e-07	5.49e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	6.11e-07	5.47e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—epilepsy syndrome	6.11e-07	5.46e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—epilepsy syndrome	6.1e-07	5.46e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GPX1—epilepsy syndrome	6.09e-07	5.45e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—epilepsy syndrome	6.09e-07	5.44e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—epilepsy syndrome	6.02e-07	5.39e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—epilepsy syndrome	6.01e-07	5.37e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AGT—epilepsy syndrome	5.98e-07	5.35e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	5.97e-07	5.34e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—epilepsy syndrome	5.97e-07	5.33e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—epilepsy syndrome	5.95e-07	5.32e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GPX1—epilepsy syndrome	5.95e-07	5.32e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—epilepsy syndrome	5.86e-07	5.24e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—epilepsy syndrome	5.86e-07	5.24e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—epilepsy syndrome	5.76e-07	5.15e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—epilepsy syndrome	5.63e-07	5.03e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—epilepsy syndrome	5.6e-07	5.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—epilepsy syndrome	5.6e-07	5e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—epilepsy syndrome	5.56e-07	4.97e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GPX1—epilepsy syndrome	5.55e-07	4.97e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—epilepsy syndrome	5.55e-07	4.96e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	5.52e-07	4.93e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—epilepsy syndrome	5.48e-07	4.9e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—epilepsy syndrome	5.44e-07	4.87e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—epilepsy syndrome	5.42e-07	4.85e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—epilepsy syndrome	5.41e-07	4.84e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AGT—epilepsy syndrome	5.34e-07	4.78e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—epilepsy syndrome	5.29e-07	4.73e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—epilepsy syndrome	5.28e-07	4.72e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—epilepsy syndrome	5.27e-07	4.72e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	5.25e-07	4.7e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—epilepsy syndrome	5.23e-07	4.68e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	5.23e-07	4.68e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AGT—epilepsy syndrome	5.21e-07	4.66e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—epilepsy syndrome	5.11e-07	4.57e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—epilepsy syndrome	5.04e-07	4.5e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—epilepsy syndrome	5.02e-07	4.49e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—epilepsy syndrome	5e-07	4.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	4.99e-07	4.46e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	4.94e-07	4.41e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TH—epilepsy syndrome	4.92e-07	4.4e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—epilepsy syndrome	4.89e-07	4.37e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AGT—epilepsy syndrome	4.87e-07	4.35e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—epilepsy syndrome	4.82e-07	4.31e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—epilepsy syndrome	4.77e-07	4.27e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—epilepsy syndrome	4.75e-07	4.24e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—epilepsy syndrome	4.59e-07	4.11e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—epilepsy syndrome	4.55e-07	4.07e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—epilepsy syndrome	4.51e-07	4.03e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—epilepsy syndrome	4.5e-07	4.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—epilepsy syndrome	4.45e-07	3.98e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—epilepsy syndrome	4.39e-07	3.92e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—epilepsy syndrome	4.18e-07	3.74e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	4.11e-07	3.67e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—epilepsy syndrome	4.1e-07	3.67e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—epilepsy syndrome	4.1e-07	3.67e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—epilepsy syndrome	4.1e-07	3.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAT—epilepsy syndrome	4.05e-07	3.62e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	4.02e-07	3.59e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—epilepsy syndrome	4e-07	3.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	3.94e-07	3.52e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—epilepsy syndrome	3.89e-07	3.48e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—epilepsy syndrome	3.88e-07	3.47e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—epilepsy syndrome	3.83e-07	3.43e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—epilepsy syndrome	3.83e-07	3.43e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—epilepsy syndrome	3.74e-07	3.34e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	3.66e-07	3.27e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	3.59e-07	3.21e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	3.5e-07	3.13e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—epilepsy syndrome	3.5e-07	3.13e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	3.27e-07	2.92e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—epilepsy syndrome	3.25e-07	2.91e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AGT—epilepsy syndrome	3.21e-07	2.87e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—epilepsy syndrome	3.15e-07	2.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—epilepsy syndrome	3.12e-07	2.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—epilepsy syndrome	2.7e-07	2.42e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—epilepsy syndrome	2.46e-07	2.2e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—epilepsy syndrome	2.39e-07	2.13e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	2.16e-07	1.93e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	2.02e-07	1.81e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—epilepsy syndrome	1.8e-07	1.61e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—epilepsy syndrome	1.76e-07	1.57e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—epilepsy syndrome	1.64e-07	1.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.08e-07	9.69e-07	CbGpPWpGaD
